| Literature DB >> 29692655 |
Hussein Sweiti1, Noor Tamimi2, Fabian Bormann1, Markus Divo3, Daniela Schulz-Ertner4, Marit Ahrens5, Ulrich Ronellenfitsch6, Matthias Schwarzbach1.
Abstract
BACKGROUND: The surgical resection of soft tissue sarcomas (STS) with sciatic nerve involvement presents a significant surgical and oncological challenge. Current treatment strategies pursue a multimodal approach with the aim of limb preservation. We aim to evaluate the outcomes of limb-sparing surgery of STS in a patient cohort and to propose a classification for STS with sciatic nerve involvement.Entities:
Year: 2018 PMID: 29692655 PMCID: PMC5859890 DOI: 10.1155/2018/6483579
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Figure 1Classification of sciatic nerve involvement and surgical treatment algorithm for lower limb STS.
Figure 2Preoperative MRI scan in a patient with type A sciatic nerve involvement and G3 pleomorphic sarcoma.
Figure 3Preoperative MRI scan in a patient with type B sciatic nerve involvement and G2 liposarcoma.
General and preoperative characteristics.
| Characteristic | Number of patients ( | % |
|---|---|---|
| Gender | ||
| Male | 12 | 44.4 |
| Female | 15 | 55.6 |
| Sides | ||
| Right | 16 | 59.3 |
| Left | 11 | 40.7 |
| Presentation status | ||
| Primary tumor | 21 | 77.8 |
| Local recurrence | 6 | 22.2 |
| Sciatic nerve involvement | ||
| Type A | 8 | 29.6 |
| Type B | 19 | 70.4 |
| Neoadjuvant therapy | ||
| External beam radiation therapy | 10 | 37.0 |
| Chemotherapy | 6 | 22.2 |
| Isolated limb perfusion | 5 | 18.5 |
Histopathologic findings.
| Characteristic | Number of patients ( | % |
|---|---|---|
| Histologic entity | ||
| Liposarcoma (all subtypes) | 13 | 48.1 |
| Pleomorphic sarcoma (all subtypes) | 11 | 40.7 |
| Malignant giant cell tumor | 1 | 3.7 |
| Myxofibrosarcoma | 1 | 3.7 |
| Primitive neuroectodermal tumor | 1 | 3.7 |
| Grade | ||
| Low grade (G1) | 10 | 37.0 |
| Intermediate grade (G2) | 5 | 18.5 |
| High grade (G3) | 12 | 44.4 |
| Maximum tumor diameter (cm) | ||
| ≥30 | 5 | 18.5 |
| 20–29 | 4 | 14.8 |
| 10–19 | 9 | 33.3 |
| <10 | 9 | 33.3 |
| Margin | ||
| Microscopically negative margins (R0) | 25 | 92.6 |
| Microscopically positive margins (R1) | 2 | 7.4 |
Postoperative morbidity.
| Number of patients ( | % | |
|---|---|---|
| Surgical complications | ||
| Wound necrosis/dehiscence | 10 | 37.0 |
| Hematoma/seroma | 6 | 22.2 |
| Fracture (after discharge) | 2 | 7.4 |
| Bleeding | 1 | 3.7 |
| Reoperations (total) | 13 | 48.1 |
| Wound revisions | 10 | 37.0 |
| Hemorrhage control | 1 | 3.7 |
| Reduction and internal fixation | 2 | 7.4 |
| Medical complications | ||
| Pneumonia | 2 | 7.4 |
| Urinary tract infection | 2 | 7.4 |
| Sepsis | 1 | 3.7 |
| Deep venous thrombosis | 1 | 3.7 |
| Hospital mortality | 0 | 0 |
Figure 4Development of metastatic disease and overall survival (p < 0.001).
Figure 5Tumor grade (G1/G2/G3) and overall survival (p=0.023).
Functional outcome.
| Number of patients ( | % | |
|---|---|---|
| Chronic leg edema | 15 | 55.6 |
| Paresthesia | 18 | 66.7 |
| Chronic pain | 12 | 44.4 |
| Walking aids/braces | 17 | 63.0 |
| Leg function/range of motion | ||
| Severely limited/no function | 9 | 33.3 |
| Limited | 12 | 44.4 |
| Normal | 6 | 22.2 |
| Walking distance | ||
| >500 m | 15 | 55.6 |
| 100–500 m | 9 | 33.3 |
| <100 m | 3 | 11.1 |